GenMark Diagnostics (GNMK) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
GenMark (GNMK) Bullish Stance Reiterated at Needham & Company on Solid Q1
May 7, 2014 9:03 AM EDTNeedham & Company analyst Mike Matson reiterated a Buy rating and $17 price target on GenMark Diagnostics (NASDAQ: GNMK) following Q1 results which did well despite a focus on NexGen.
Matson comments, "GNMK's 1Q14 results were ahead of consensus and management maintained 2014 revenue guidance.... More
